Physician profile
Steven R White
NPI 1922161447
$969,543.26
in general payments reported to CMS, 2019-2025
14 companies · $288K in 2025
The $288K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,578 · 2021: $54K · 2022: $109K · 2023: $215K · 2024: $287K · 2025: $288K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $654K · Travel and Lodging: $68K · Consulting Fee: $56K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $653,583.32 |
| Travel and Lodging | $68,469.09 |
| Consulting Fee | $56,352.00 |
| Food and Beverage | $11,267.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $453,077.27 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $304,656.75 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $199,948.06 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Genentech USA, INC. | $5,776.50 | 2019-2025 | Xolair, Actemra |
| Boehringer Ingelheim International Gmbh | $3,561.32 | 2019 | |
| Glaxosmithkline, LLC. | $2,156.87 | 2019-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $107.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.36 | 2020-2025 | Glassia |
| Amgen INC. | $59.27 | 2023-2024 | Tezspire |
| Henry Schein, INC. | $48.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.11 | 2019 | |
| Verona Pharma, INC. | $23.09 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $13.79 | 2023 | Yupelri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.